Assessment of safety and long-term outcomes of initial treatment with Placebo in TADS

Betsy D. Kennard, Susan G. Silva, Taryn L. Mayes, Paul Rohde, Jennifer L. Hughes, Benedetto Vitiello, Christopher J. Kratochvil, John F. Curry, Graham J. Emslie, Mark A. Reinecke, John S. March

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective: The authors examined whether initial assignment to receive placebo for 12 weeks followed by open active treatment as clinically indicated was associated with different levels of benefit and risk of harm across 36 weeks as compared with initial assignment to receive active treatments. Method: Adolescents with major depressive disorder (N=439) were randomly assigned to receive an initial 12 weeks of treatment with fluoxetine, cognitive-behavioral therapy (CBT), combination treatment with fluoxetine and CBT, or clinical management with placebo; those assigned to placebo received open active treatment as clinically indicated after 12 weeks of placebo. Assessments were conducted every 6 weeks for 36 weeks. The primary outcome measures were response and remission based on scores on the Children's Depression Rating Scale-Revised and the Clinical Global Impression improvement subscale. Results: At week 36, the response rate was 82% in the placebo/open group and 83% in the active treatment groups. The remission rate was 48% in the placebo/open group and 59% in the act ive treatment groups, a difference that approached statistical significance. Patients who responded to placebo generally retained their response. Those who did not respond to placebo subsequently responded to active treatment at the same rate as those initially assigned to active treatments. There were no differences between groups in rates of suicidal events, study retention, or symptom worsening. Conclusions: Remis s ion rates at 9 months were lower in patients treated initially with placebo, but 3 months of placebo treatment was not associated with any harm or diminished response to subsequent treatment.

Original languageEnglish (US)
Pages (from-to)337-344
Number of pages8
JournalAmerican Journal of Psychiatry
Volume166
Issue number3
DOIs
StatePublished - Mar 2009

Fingerprint

Placebos
Safety
Therapeutics
Fluoxetine
Cognitive Therapy
Major Depressive Disorder
Outcome Assessment (Health Care)
Ions
Depression

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Assessment of safety and long-term outcomes of initial treatment with Placebo in TADS. / Kennard, Betsy D.; Silva, Susan G.; Mayes, Taryn L.; Rohde, Paul; Hughes, Jennifer L.; Vitiello, Benedetto; Kratochvil, Christopher J.; Curry, John F.; Emslie, Graham J.; Reinecke, Mark A.; March, John S.

In: American Journal of Psychiatry, Vol. 166, No. 3, 03.2009, p. 337-344.

Research output: Contribution to journalArticle

Kennard, BD, Silva, SG, Mayes, TL, Rohde, P, Hughes, JL, Vitiello, B, Kratochvil, CJ, Curry, JF, Emslie, GJ, Reinecke, MA & March, JS 2009, 'Assessment of safety and long-term outcomes of initial treatment with Placebo in TADS', American Journal of Psychiatry, vol. 166, no. 3, pp. 337-344. https://doi.org/10.1176/appi.ajp.2008.08040487
Kennard, Betsy D. ; Silva, Susan G. ; Mayes, Taryn L. ; Rohde, Paul ; Hughes, Jennifer L. ; Vitiello, Benedetto ; Kratochvil, Christopher J. ; Curry, John F. ; Emslie, Graham J. ; Reinecke, Mark A. ; March, John S. / Assessment of safety and long-term outcomes of initial treatment with Placebo in TADS. In: American Journal of Psychiatry. 2009 ; Vol. 166, No. 3. pp. 337-344.
@article{a78b82a697f745aeafee3455fa6e4890,
title = "Assessment of safety and long-term outcomes of initial treatment with Placebo in TADS",
abstract = "Objective: The authors examined whether initial assignment to receive placebo for 12 weeks followed by open active treatment as clinically indicated was associated with different levels of benefit and risk of harm across 36 weeks as compared with initial assignment to receive active treatments. Method: Adolescents with major depressive disorder (N=439) were randomly assigned to receive an initial 12 weeks of treatment with fluoxetine, cognitive-behavioral therapy (CBT), combination treatment with fluoxetine and CBT, or clinical management with placebo; those assigned to placebo received open active treatment as clinically indicated after 12 weeks of placebo. Assessments were conducted every 6 weeks for 36 weeks. The primary outcome measures were response and remission based on scores on the Children's Depression Rating Scale-Revised and the Clinical Global Impression improvement subscale. Results: At week 36, the response rate was 82{\%} in the placebo/open group and 83{\%} in the active treatment groups. The remission rate was 48{\%} in the placebo/open group and 59{\%} in the act ive treatment groups, a difference that approached statistical significance. Patients who responded to placebo generally retained their response. Those who did not respond to placebo subsequently responded to active treatment at the same rate as those initially assigned to active treatments. There were no differences between groups in rates of suicidal events, study retention, or symptom worsening. Conclusions: Remis s ion rates at 9 months were lower in patients treated initially with placebo, but 3 months of placebo treatment was not associated with any harm or diminished response to subsequent treatment.",
author = "Kennard, {Betsy D.} and Silva, {Susan G.} and Mayes, {Taryn L.} and Paul Rohde and Hughes, {Jennifer L.} and Benedetto Vitiello and Kratochvil, {Christopher J.} and Curry, {John F.} and Emslie, {Graham J.} and Reinecke, {Mark A.} and March, {John S.}",
year = "2009",
month = "3",
doi = "10.1176/appi.ajp.2008.08040487",
language = "English (US)",
volume = "166",
pages = "337--344",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "3",

}

TY - JOUR

T1 - Assessment of safety and long-term outcomes of initial treatment with Placebo in TADS

AU - Kennard, Betsy D.

AU - Silva, Susan G.

AU - Mayes, Taryn L.

AU - Rohde, Paul

AU - Hughes, Jennifer L.

AU - Vitiello, Benedetto

AU - Kratochvil, Christopher J.

AU - Curry, John F.

AU - Emslie, Graham J.

AU - Reinecke, Mark A.

AU - March, John S.

PY - 2009/3

Y1 - 2009/3

N2 - Objective: The authors examined whether initial assignment to receive placebo for 12 weeks followed by open active treatment as clinically indicated was associated with different levels of benefit and risk of harm across 36 weeks as compared with initial assignment to receive active treatments. Method: Adolescents with major depressive disorder (N=439) were randomly assigned to receive an initial 12 weeks of treatment with fluoxetine, cognitive-behavioral therapy (CBT), combination treatment with fluoxetine and CBT, or clinical management with placebo; those assigned to placebo received open active treatment as clinically indicated after 12 weeks of placebo. Assessments were conducted every 6 weeks for 36 weeks. The primary outcome measures were response and remission based on scores on the Children's Depression Rating Scale-Revised and the Clinical Global Impression improvement subscale. Results: At week 36, the response rate was 82% in the placebo/open group and 83% in the active treatment groups. The remission rate was 48% in the placebo/open group and 59% in the act ive treatment groups, a difference that approached statistical significance. Patients who responded to placebo generally retained their response. Those who did not respond to placebo subsequently responded to active treatment at the same rate as those initially assigned to active treatments. There were no differences between groups in rates of suicidal events, study retention, or symptom worsening. Conclusions: Remis s ion rates at 9 months were lower in patients treated initially with placebo, but 3 months of placebo treatment was not associated with any harm or diminished response to subsequent treatment.

AB - Objective: The authors examined whether initial assignment to receive placebo for 12 weeks followed by open active treatment as clinically indicated was associated with different levels of benefit and risk of harm across 36 weeks as compared with initial assignment to receive active treatments. Method: Adolescents with major depressive disorder (N=439) were randomly assigned to receive an initial 12 weeks of treatment with fluoxetine, cognitive-behavioral therapy (CBT), combination treatment with fluoxetine and CBT, or clinical management with placebo; those assigned to placebo received open active treatment as clinically indicated after 12 weeks of placebo. Assessments were conducted every 6 weeks for 36 weeks. The primary outcome measures were response and remission based on scores on the Children's Depression Rating Scale-Revised and the Clinical Global Impression improvement subscale. Results: At week 36, the response rate was 82% in the placebo/open group and 83% in the active treatment groups. The remission rate was 48% in the placebo/open group and 59% in the act ive treatment groups, a difference that approached statistical significance. Patients who responded to placebo generally retained their response. Those who did not respond to placebo subsequently responded to active treatment at the same rate as those initially assigned to active treatments. There were no differences between groups in rates of suicidal events, study retention, or symptom worsening. Conclusions: Remis s ion rates at 9 months were lower in patients treated initially with placebo, but 3 months of placebo treatment was not associated with any harm or diminished response to subsequent treatment.

UR - http://www.scopus.com/inward/record.url?scp=62949248385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62949248385&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2008.08040487

DO - 10.1176/appi.ajp.2008.08040487

M3 - Article

VL - 166

SP - 337

EP - 344

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 3

ER -